NMTRQ has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
NMTRQ has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
9 Meters Biopharma's revenue for the three months ended in Mar. 2023 was $0.00 Mil. Its revenue for the trailing twelve months (TTM) ended in Mar. 2023 was $0.00 Mil. 9 Meters Biopharma's Revenue per Share for the three months ended in Mar. 2023 was $0.00. Its Revenue per Share for the trailing twelve months (TTM) ended in Mar. 2023 was $0.00.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get other companies' revenue growth rate using Revenue per Share data.
The historical data trend for 9 Meters Biopharma's Revenue can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
9 Meters Biopharma Annual Data | |||||||||||||||||||||
Trend | Dec13 | Dec14 | Dec15 | Dec16 | Dec17 | Dec18 | Dec19 | Dec20 | Dec21 | Dec22 | |||||||||||
Revenue | Get a 7-Day Free Trial | - | - | - | - | - |
9 Meters Biopharma Quarterly Data | ||||||||||||||||||||
Jun18 | Sep18 | Dec18 | Mar19 | Jun19 | Sep19 | Dec19 | Mar20 | Jun20 | Sep20 | Dec20 | Mar21 | Jun21 | Sep21 | Dec21 | Mar22 | Jun22 | Sep22 | Dec22 | Mar23 | |
Revenue | Get a 7-Day Free Trial | - | - | - | - | - |
For the Biotechnology subindustry, 9 Meters Biopharma's Revenue, along with its competitors' market caps and Revenue data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
For the Biotechnology industry and Healthcare sector, 9 Meters Biopharma's Revenue distribution charts can be found below:
* The bar in red indicates where 9 Meters Biopharma's Revenue falls into.
Also referred as sales, revenue is income that a company receives from its normal business activities, usually from the sale of goods and services to customers. Revenue is often referred to as the "top line" due to its position on the income statement at the very top.
Revenue for the trailing twelve months (TTM) ended in Mar. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.00 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
9 Meters Biopharma (OTCPK:NMTRQ) Revenue Explanation
In ranking the predictability, companies with more consistent revenue and earnings growth are ranked high with predictability.
Peter Lynch categorized companies according to their revenue growth:
His favorite companies are stalwart, those growing between 10-20% a year.
Companies in cyclical industries may see their revenue fluctuate wildly in good years and bad years.
Be Aware
Revenue can be manipulated by changing the way how revenue is booked. Companies may book sales before the payment is received, or before the revenue is fully earned. These will be added to balance sheet items such as account payable or account receivables.
Thank you for viewing the detailed overview of 9 Meters Biopharma's Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.
Bethany Sensenig | officer: Chief Financial Officer | C/O 9 METERS BIOPHARMA, INC., 8480 HONEYCUTT ROAD, SUITE 120, RALEIGH NC 27615 |
John Temperato | director, officer: Chief Executive Officer | C/O MELINTA THERAPEUTICS,INC., 300 GEORGE STREET, SUITE 301, NEW HAVEN CT 06511 |
Mark A Sirgo | director | C/O BIODELIVERY SCIENCES INTERNATIONAL, 801 CORPORATE CENTER DRIVE -SUITE 210, RALEIGH NC 27607 |
Michael T. Constantino | director | C/O 9 METERS BIOPHARMA, INC., 8480 HONEYCUTT ROAD, SUITE 120, RALEIGH NC 27615 |
Samantha Ventimiglia | director | C/O 9 METERS BIOPHARMA, INC., 8480 HONEYCUTT ROAD, SUITE 120, RALEIGH NC 27615 |
Edward J Sitar | officer: Chief Financial Officer | 39 FLAMING ARROW ROAD, MAHWAH NJ 07430 |
Orbimed Israel Biofund Gp Limited Partnership | 10 percent owner | 601 LEXINGTON AVENUE, 54TH FLOOR, NEW YORK NY 1022-4629 |
Yehuda Michael Rice | director | 155 WALNUT STREET, ENGLEWOOD NJ 07631 |
Nissim Darvish | director, 10 percent owner | C/O INNOVATE BIOPHARMACEUTICALS, INC., 8480 HONEYCUTT ROAD, SUITE 120, RALEIGH NC 27615 |
Orbimed Israel Gp Ltd. | 10 percent owner | 601 LEXINGTON AVENUE, 54TH FLOOR, NEW YORK NY 10022-4629 |
Sandeep Laumas | director, officer: Executive Chairman | 8480 HONEYCUTT RD, SUITE 200, RALEIGH NC 27615 |
Jay P. Madan | director, officer: President | 8480 HONEYCUTT RD, SUITE 200, RALEIGH NC 27615 |
Roy Proujansky | director | 144 PAU NEL DRIVE, LANDENBERG PA 19350 |
Christopher P. Prior | director, officer: Chief Executive Officer | 8480 HONEYCUTT RD, SUITE 200, RALEIGH NC 27615 |
June Sherie Almenoff | officer: COO and Chief Medical Officer | C/O BRAINSTORM CELL THERAPEUTICS INC., 1325 AVENUE OF AMERICAS 28TH FLOOR, NEW YORK NY 10019 |
From GuruFocus
By ACCESSWIRE ACCESSWIRE • 11-14-2022
By ACCESSWIRE ACCESSWIRE • 05-19-2022
By ACCESSWIRE ACCESSWIRE • 06-21-2022
By ACCESSWIRE ACCESSWIRE • 04-13-2022
By ACCESSWIRE ACCESSWIRE • 08-15-2022
By ACCESSWIRE ACCESSWIRE • 05-18-2022
By ACCESSWIRE ACCESSWIRE • 05-16-2022
By ACCESSWIRE ACCESSWIRE • 03-28-2023
By ACCESSWIRE ACCESSWIRE • 11-08-2022
By ACCESSWIRE ACCESSWIRE • 02-25-2022
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.